Protalix BioTherapeutics Files 8-K

Ticker: PLX · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1006281

Protalix Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyProtalix Biotherapeutics, Inc. (PLX)
Form Type8-K
Filed DateOct 17, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, financials

Related Tickers: PLX

TL;DR

PLX filed an 8-K on 10/17/25, mostly financial docs & other events. No major news yet.

AI Summary

On October 17, 2025, Protalix BioTherapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Protalix BioTherapeutics is providing updated information to the SEC, which could include financial updates or disclosures of other material events relevant to investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.

Key Players & Entities

  • Protalix BioTherapeutics, Inc. (company) — Registrant
  • 0001104659-25-100264 (filing_id) — Accession Number
  • October 17, 2025 (date) — Filing Date

FAQ

What is the primary purpose of this 8-K filing for Protalix BioTherapeutics?

The filing is for a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on October 17, 2025, and includes information on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is Protalix BioTherapeutics, Inc.

In which state was Protalix BioTherapeutics, Inc. incorporated?

Protalix BioTherapeutics, Inc. was incorporated in Delaware.

What is the IRS Employer Identification No. for Protalix BioTherapeutics, Inc.?

The IRS Employer Identification No. for Protalix BioTherapeutics, Inc. is 65-0643773.

What are the business address details provided for Protalix BioTherapeutics, Inc.?

The business address is 2 University Plaza, Suite 100, Hackensack, NJ 07601.

Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2025-10-17 08:08:41

Key Financial Figures

  • $0.001 — ange on which registered Common stock, $0.001 par value PLX NYSE American Indic

Filing Documents

01

Item 7.01 Regulation FD Disclosure On October 17, 2025, Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company") posted a corporate presentation to its website. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 to this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01

Item 8.01 Other Events On October 17, 2025, the Company issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announcing that that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a negative opinion on the request to approve the dosing regimen of 2 mg/kg body weight infused every 4 weeks for Elfabrio (pegunigalsidase alfa), in addition to the currently approved dosing regimen of 1 mg/kg body weight infused every 2 weeks . A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 October 2025 Corporate Presentation 99.2 Press Release dated October 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 17, 2025 PROTALIX BIOTHERAPEUTICS, INC. By: /s/ Dror Bashan Name: Dror Bashan Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.